Itch company Trevi files for IPO

With a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc. (New Haven, Conn.) is seeking to raise up to $86.3 million in an IPO.

The company's PRISM study, which is evaluating nalbuphine ER in patients with prurigo nodularis, is due to generate top-line data in 1H20. Trevi plans to conduct another Phase III study before submitting regulatory applications for nalbuphine ER...